NCT00150007已完成4 期
Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 335
- 主要终点
- Improvement in Gastro intestinal (GI) symptom severity and health-related quality of life (HRQoL) in patients with GI complaints who are converted from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS)
研究概览
简要总结
The purpose of this study is to assess the impact that GI complaints have on patient reported outcomes in renal transplant recipients and to determine if there is improvement in patient reported outcomes when patients are converted to a EC-MPS-based immunosuppressive treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received kidney transplant at least 1 month prior to study enrollment;
- •Receiving immunosuppressive regimen that includes MMF for at least 2 weeks prior to study enrollment;
- •Eligible to convert to EC-MPS because of GI complaints OR not currently experiencing GI complaints and stable on current immunosuppressive regimen;
- •At least 18 years of age;
- •Willing to provide written informed consent; and
- •Able to meet all study requirements including completing paper questionnaires and completing two study visits.
排除标准
- •GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea);
- •Acute rejection < 1 week prior to study enrollment;
- •Woman of child-bearing potential who is planning to become pregnant or is pregnant and/or lactating who is unwilling to use effective means of contraception;
- •Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements;
- •Undergoing acute medical intervention or hospitalization;
- •Any other medical condition that, in the opinion of the site investigator based on recall or chart review, would interfere with completing the study, including but not limited to, visual problems or cognitive impairment
- •Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Improvement in Gastro intestinal (GI) symptom severity and health-related quality of life (HRQoL) in patients with GI complaints who are converted from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS)
次要结局
- Impact of GI symptoms on patients' perceptions of symptom severity, GI-specific HRQoL, and general HRQoL.
研究者
相似试验
已完成
4 期
Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) SymptomsRenal TransplantNCT00529269Novartis Pharmaceuticals200
已完成
不适用
Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) SymptomsKidney TransplantationGI Symptoms SeverityNCT01300416Novartis Pharmaceuticals101
已完成
不适用
Iron Supplementation and Side EffectsIron OverloadIron Deficiency AnemiaNCT04018300Iowa State University17
已完成
不适用
PROMIS and Patient SatisfactionAnkle PathologyFoot PathologyNCT04654910University of Rochester275
已完成
不适用
Virtual Phone Visits Compared to In-Person Physical Visits for Post-Operative Follow-Up at a Sports Medicine ClinicPatient SatisfactionSurgeryOrthopedic DisorderSports InjuryNCT05998148Jonathan Wu90